간행물

Journal of Gynecologic Oncology (JGO) update

  • : 대한부인종양학회(구 대한부인종양·콜포스코피학회)
  • : 의약학분야  >  산부인과학
  • : KCI등재
  • : SCI,SCOPUS
  • : 연속간행물
  • : 격월
  • : 2005-0380
  • :
  • : 대한부인종양.콜포스코피학회잡지(~2004)→부인종양(2005~)→Journal of Gynecologic Oncolgy (JGO)(2008~)

수록정보
29권2호(2018) |수록논문 수 : 11
간행물 제목
29권2호(2018년) 수록논문
권호별 수록 논문
| | | |

KCI등재 SCI SCOPUS

1Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis

저자 : E Sun Paik , Tae-joong Kim , Chel Hun Choi , Byoung-gie Kim , Duk-soo Bae , Jeong-won Lee

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 29권 2호 발행 연도 : 2018 페이지 : pp. 1-11 (11 pages)

다운로드

(기관인증 필요)

초록보기

Objective: The aim of this investigation is to compare outcomes of patients according to the presence of cancer arising from endometriosis in ovarian clear cell carcinoma (CCC) and endometrioid carcinoma (EC).
Methods: This study retrospectively investigated 224 CCC and EC patients treated in Samsung Medical Center from 2001 to 2015 to identify cancer arising from endometriosis according to Sampson and Scott criteria. Propensity score matching was performed to compare patients arising from endometriosis to patients without endometriosis (ratio 1:1) according to stage, age, lymph node metastasis (LNM), cancer antigen (CA)-125 level, and residual status after debulking surgery.
Results: Forty-five cases arising from endometriosis were compared with 179 cases without endometriosis. CCC and EC arising from endometriosis tended to present with early age (mean, 45.2 vs. 49.2 years; p=0.003), early-stage (stages I and II, 92.7% vs. 62.3%; p<0.001), lower CA-125 level (mean, 307.1 vs. 556.7; p=0.041), higher percentages of no gross residual disease after surgery (87.8% vs.56.8%; p=0.001), and higher percentages of negative LNM (82.9% vs. 59.0%; p=0.008) compared to cases without endometriosis. Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) showed better outcomes for groups with cancer arising from endometriosis (p=0.014 for PFS; and p=0.010 for OS). However, the association with endometriosis was not significant in multivariate analysis. Also, after propensity score matching, survival differences between the 2 groups were not significant.
Conclusion: CCC and EC arising from endometriosis are diagnosed at an earlier age and stage. However, cancer arising from endometriosis was not a significant prognostic factor.

KCI등재 SCI SCOPUS

2Major clinical research advances in gynecologic cancer in 2017

저자 : Dong Hoon Suh , Miseon Kim , Kyung-hun Lee , Keun-yong Eom , Maj Kamille Kjeldsen , Mansoor Raza Mirza , Jae-weon Kim

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 29권 2호 발행 연도 : 2018 페이지 : pp. 1-18 (18 pages)

다운로드

(기관인증 필요)

초록보기

In 2017, 10 topics were selected as major clinical research advances in gynecologic oncology. For cervical cancer, efficacy and safety analysis results of a 9-valent human papillomavirus (HPV) vaccine and long-term impact of reduced dose of quadrivalent vaccine were updated. Brief introduction of KEYNOTE trials of pembrolizumab, a monoclonal antibody that blocks the interaction between programmed death (PD)-1 and its ligands, PD-L1 and PD-L2, followed. Tailored surveillance programs for gynecologic cancer related with Lynch syndrome and update on sentinel lymph node mapping were reviewed for uterine corpus cancer. For ovarian cancer, 5 topics were selected including poly(ADP-ribose) polymerases inhibitors and immunotherapy. The other potential practice changers covered in this review were lymphadenectomy in advanced disease, secondary cytoreductive surgery in recurrent disease, weekly dose-dense regimen for first-line chemotherapy, incorporation of bevacizumab maintenance in platinum-sensitive recurrent disease, and effect of platinum-free interval prolongation. Conflicting opinions of academic societies on periodic pelvic examination were introduced in conjunction with relevant literature review. For the field of radiation oncology, results of 2 big trials, The Postoperative Radiation Therapy in Endometrial Carcinoma-3 and Gynecologic Oncology Group-258, for endometrial cancer and recent advance in high-dose-rate brachytherapy for cervical cancer were reported. Topics for breast cancer covered adjuvant capecitabine after preoperative chemotherapy, adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive disease, olaparib for metastatic cancer in patients with a germline BRCA mutation, 20-year risks of recurrence after stopping endocrine therapy at 5 years, and contemporary hormonal contraception and the risk of breast cancer.

KCI등재 SCI SCOPUS

3Impact of adjuvant hysterectomy on prognosis in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy: a meta-analysis

저자 : Seung-hyuk Shim , Soo-nyung Kim , Su Hyun Chae , Jung Eun Kim , Sun Joo Lee

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 29권 2호 발행 연도 : 2018 페이지 : pp. 1-18 (18 pages)

다운로드

(기관인증 필요)

초록보기

Objective: Few data exist regarding adjuvant hysterectomy (AH) in locally advanced cervical cancer (LACC) patients treated with chemoradiotherapy. We investigated the effect of AH on prognosis in LACC patients, through meta-analysis.
Methods: EMBASE and MEDLINE databases and the Cochrane Library were searched for published studies comparing LACC patients who received AH after chemoradiotherapy with those who did not, through April 2016. Endpoints were mortality and recurrence rates. For pooled estimates of the effect of AH on mortality/recurrence, random- or fixed-effects meta-analytical models were used.
Results: Two randomized trials and six observational studies (AH following chemoradiotherapy, 630 patients; chemoradiotherapy, 585 patients) met our search criteria. Fixed-effects model-based meta-analysis indicated no significant difference in mortality between the groups (odds ratio [OR]=1.01; 95% confidence interval [CI]=0.58-1.78; p=0.968) with low cross-study heterogeneity (p=0.73 and I2=0.0). This pattern was observed in subgroup analysis for study design, radiation type, response after chemoradiotherapy, and hysterectomy type. The pooled OR for AH and recurrence was 0.59 (95% CI=0.44-0.79; p<0.05) with low cross-study heterogeneity (p=0.29 and I2=17.8), favoring the AH group. However, this pattern was not observed in the subgroup analysis for the randomized trials. There was no evidence of publication bias.
Conclusion: In this meta-analysis, AH following chemoradiotherapy did not improve survival in patients with LACC, although it seemed to reduce the risk of recurrence. Concerning the significant morbidity of AH after chemoradiotherapy, routine use of AH should be avoided.

KCI등재 SCI SCOPUS

4Trends in single women with malignancy of the uterine cervix in United States

저자 : Hiroko Machida , Erin A. Blake , Sarah E. Eckhardt , Tsuyoshi Takiuchi , Brendan H. Grubbs , Mikio Mikami , Lynda D. Roman , Koji Matsuo

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 29권 2호 발행 연도 : 2018 페이지 : pp. 1-11 (11 pages)

다운로드

(기관인증 필요)

초록보기

Objective: To examine trends and characteristics of single women with malignancy of the uterine cervix.
Methods: This is a retrospective observational study examining the United States population-based tumor registry (the Surveillance, Epidemiology, and End Results program). Time-specific trends in single marital status were examined in 3,294,208 women among 12 common female malignancies including 87,151 women with uterine cervical malignancy between 1973 and 2013.
Results: While the proportion of single women in the majority of malignancies increased during the study time, the proportion of single women with cervical malignancy significantly increased more than in other malignancies (29.3% in 2013 from 6.3% in 1973). There was a surge in the proportion of single women with cervical malignancy starting in the early 1990s, exhibiting the largest annual percentage rate change (APC) among all examined malignancies (1.8%; 95% confidence interval [CI]=1.6, 2.0; p<0.001). There was a significant decrease in the proportion of women aged <40 years with cervical malignancy between 1989 and 2013 (APC, -1.2%; 95% CI=-1.4, -1.0; p<0.001). However, when stratified by age, the proportion of single women aged ≥40 years increased significantly during the time (APC, 2.7%; 95% CI=2.3, 3.2; p<0.001) but did not in those who were <40 years (APC, 0.1%; 95% CI=-0.7, 0.6; p=0.850).
Conclusion: The proportion of single women with malignancy of the uterine cervix has significantly increased in the past 4 decades. This increase was most dramatic in single women aged ≥40 years. Improving screening strategies in single women aged ≥40 years may help reduce the incidence of this malignancy.

KCI등재 SCI SCOPUS

5Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism

저자 : Shan-shan Li , Jing Ma , Alice S. T. Wong

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 29권 2호 발행 연도 : 2018 페이지 : pp. 1-11 (11 pages)

다운로드

(기관인증 필요)

초록보기

Ovarian cancer is most deadly gynecologic malignancies worldwide. Chemotherapy is the mainstay treatment for ovarian cancer. Despite the initial response is promising, frequent recurrence in patients with advanced diseases remains a therapeutic challenge. Thus, understanding the biology of chemoresistance is of great importance to overcome this challenge and will conceivably benefit the survival of ovarian cancer patients. Although mechanisms underlying the development of chemoresistance are still ambiguous, accumulating evidence has supported an integral role of cancer stem cells (CSCs) in recurrence following chemotherapy. Recently, tumor metabolism has gained interest as a reason of chemoresistance in tumors and chemotherapeutic drugs in combination with metabolism targeting approaches has been found promising in overcoming therapeutic resistance. In this review, we will summarize recent studies on CSCs and metabolism in ovarian cancer and discuss possible role of CSCs metabolism in chemoresistance.

KCI등재 SCI SCOPUS

6Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer

저자 : Mikio Mikami , Masako Shida , Takeo Shibata , Hidetaka Katabuchi , Junzo Kigawa , Daisuke Aoki , Nobuo Yaegashi

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 29권 2호 발행 연도 : 2018 페이지 : pp. 1-11 (11 pages)

다운로드

(기관인증 필요)

초록보기

Objective: The Japan Society of Gynecologic Oncology (JSGO) initiated a nation-wide training system for the education and certification for gynecologic oncologists in 2005. To assess the impact of the quality of the JSGO-accredited institutions, JSGO undertook an analysis of the Uterine Cervical Cancer Registry of the Japan Society of Obstetrics and Gynecology (JSOG) to determine the effectiveness of the JSGO-accredited institutions on the treatment and survival of women with cervical cancer.
Methods: The effectiveness of 119 JSGO-accredited institutions and 125 non-JSGO-accredited institutions on the treatment and survival of women with cervical cancer were compared by analyzing the tumor characteristics, treatment patterns, and survival outcomes of women with stage T1B-T4 cervical cancer utilizing the data in the JSOG nation-wide registry for cervical cancer (2006-2009).
Results: A total of 14,185 eligible women were identified: 10,920 (77.0%) cases for 119 JSGO-accredited institutions and 3,265 (23.0%) cases for 125 non-accredited institutions. A multivariate analysis showed that age, stage, histology type, and treatment pattern were independently associated with mortality. Moreover, women who received treatment at the JSGO-accredited institutions had a significantly decreased mortality risk compared to non-accredited institutions (adjusted hazard ratio [aHR]=0.843; 95% confidence interval [CI]=0.784-0.905). Similar findings on multivariate analysis were seen among subset of women who received surgery alone (aHR=0.552; 95% CI=0.393-0.775) and among women who received radiotherapy (aHR=0.845; 95% CI=0.766-0.931).
Conclusion: Successful implementation of gynecologic oncology accrediting institution was associated with improved survival outcome of women with cervical cancer in Japan.

KCI등재 SCI SCOPUS

7Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?

저자 : Wataru Yamagami , Nobuyuki Susumu , Takeshi Makabe , Kensuke Sakai , Hiroyuki Nomura , Fumio Kataoka , Akira Hirasawa , Kouji Banno , Daisuke Aoki

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 29권 2호 발행 연도 : 2018 페이지 : pp. 1-12 (12 pages)

다운로드

(기관인증 필요)

초록보기

Objective: Reports on the repeated administration of medroxyprogesterone acetate (MPA) for intrauterine recurrence after fertility-preserving therapy for atypical endometrial hyperplasia (AEH) and early grade 1 endometrioid carcinoma (G1) are lacking. We aimed to clarify the outcomes of repeated MPA therapy in cases of intrauterine recurrence after fertility-preserving therapy with MPA against AEH/early G1.
Methods: Patients with AEH or stage IA well-differentiated endometrioid carcinoma without myometrial invasion who underwent first-line MPA therapy for primary lesions or intrauterine recurrence were divided into initial treatment and repeated treatment groups (162 and 82 patients, respectively). Oral MPA administration (400-600 mg/day) was continued until pathological tumor disappearance. Data regarding clinicopathological factors, adverse events, and outcomes following the initial and repeated hormonal treatments were extracted from medical records and analyzed.
Results: Complete response rates in the initial and repeated treatment groups were 98.5% and 96.4%, respectively, among patients with AEH, and were 90.7% and 98.1%, respectively, among patients with G1. In the initial treatment group, 5-year recurrence-free survival (RFS) rates were 53.7% and 33.2% among patients with AEH and G1, respectively. In the repeated treatment group, RFS rates were 14.0% and 11.2% among patients with AEH and G1, respectively. Among patients with AEH, the pregnancy rate tended to be lower in the repeated treatment group than in the initial treatment group (11.1% vs. 29.2%; p=0.107), while no significant group difference was observed among patients with G1 (20.8% vs. 22.7%).
Conclusion: Repeated treatment is sufficiently effective for intrauterine recurrence after hormonal therapy for AEH/early G1.

KCI등재 SCI SCOPUS

8Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis

저자 : Morikazu Miyamoto , Masashi Takano , Tadashi Aoyama , Hiroaki Soyama , Tomoyuki Yoshikawa , Hitoshi Tsuda , Kenichi Furuya

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 29권 2호 발행 연도 : 2018 페이지 : pp. 1-8 (8 pages)

다운로드

(기관인증 필요)

초록보기

Objective: In 2014 World Health Organization criteria, seromucinous carcinoma was defined as a new histological subtype in ovarian carcinomas, but “seromucinous carcinoma” was not defined in endometrial carcinomas. The aim of this study was to identify seromucinous carcinoma resembling ovarian seromucinous carcinoma in endometrial carcinomas, and to evaluate the clinical significance for prognoses of the patients.
Methods: Central pathological review was conducted for patients with endometrioid carcinoma of the endometrium treated by primary surgery at our hospital between 1990 and 2013.
Results: Among 340 cases included in the study, no case had all tumor cells resembling ovarian seromucinous carcinoma in all specimens, and 31 cases (9.1%) had seromucinous component in combination with endometrioid carcinomas. Immunohistochemical analysis revealed seromucinous component had positive reactivity for cytokeratin (CK) 7, and negative reactivity for CK20 and caudal type homeobox 2 (CDX2) in all cases. Seromucinous component showed lower immunoreactivity of estrogen receptor and progesterone receptor, compared with endometrioid carcinoma component. Progression-free survival of the cases with seromucinous component was better than those without seromucinous component (p=0.049).
Conclusion: Seromucinous component was identified in approximately 10% of endometrioid carcinoma, and could be a histological predictor for prognosis.

KCI등재 SCI SCOPUS

9Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma

저자 : Hiroyuki Yamazaki , Yukiharu Todo , Chisa Shimada , Sho Takeshita , Shinichiro Minobe , Kazuhira Okamoto , Katsushige Yamashiro , Hidenori Kato

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 29권 2호 발행 연도 : 2018 페이지 : pp. 1-11 (11 pages)

다운로드

(기관인증 필요)

초록보기

Objectives: This study evaluated the therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma (OCCC).
Methods: We retrospectively reviewed records of 127 consecutive patients with pT1/pT2 and M0 OCCC who were treated between January 1995 and December 2015. We compared survival outcomes between those who did and did not undergo para-aortic lymph node dissection (PAND), and analyzed independent prognostic factors (Cox proportional hazards model with backward stepwise elimination).
Results: Of the 127 patients, 36 (28%) did not undergo lymphadenectomy; 12 (10%) patients underwent pelvic lymph node dissection (PLND) only; and 79 (62%) patients underwent both PLND and PAND. Of the 91 patients with lymphadenectomy, 11 (12%) had lymph node metastasis (LNM). The PAND- and PAND+ groups did not significantly differ in age, distribution of pT status, radiologically enlarged lymph nodes, positive peritoneal cytology, capsule rupture, peritoneal involvement, and combined chemotherapy. Cox regression multivariate analysis confirmed that older age (hazard ratio [HR]=2.1; 95% confidence interval [CI]=1.0-4.3), LNM (HR=4.4; 95% CI=1.7-11.6), and positive peritoneal cytology (HR=4.2; 95% CI=2.1-8.4) were significantly and independently related to poor disease-specific survival (DSS), but implementation of both PLND and PAND (HR=0.4; 95% CI=0.2-0.8) were significantly and independently related to longer DSS.
Conclusion: Although few in number, there are some patients with early-stage OCCC who can benefit from full lymphadenectomy. Its therapeutic role should be continuously investigated in OCCC patients at potential risk of LNM.

KCI등재 SCI SCOPUS

10Trends of uterine carcinosarcoma in the United States

저자 : Koji Matsuo , Malcolm S. Ross , Hiroko Machida , Erin A. Blake , Lynda D. Roman

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 29권 2호 발행 연도 : 2018 페이지 : pp. 1-11 (11 pages)

다운로드

(기관인증 필요)

초록보기

Objective: Uterine carcinosarcoma (UCS) is a rare type of high-grade endometrial cancer (EC) that has been understudied with population-based statistics due to its rarity. This study examined temporal trends in the proportion of UCS among women with EC.
Methods: This is a retrospective observational study examining The Surveillance, Epidemiology, and End Results program between 1973-2013. Primary EC cases were eligible for analysis, and a time-specific proportion of UCS was examined during the study period.
Results: UCS was seen in 11,000 (4.7%) women among 235,849 primary EC cases. Mean age at UCS diagnosis increased from 65.9 to 71.7 years between 1973-1989 and then decreased from 71.7 to 67.0 years between 1989-2013 (both, p<0.001). Proportion of Black women significantly increased during the study period (11.9%-20.0%, p<0.001), whereas the proportion of White women decreased from 86.0% to 60.5% between 1987-2013 (p<0.001). There was a significant increase in the proportion of UCS among primary EC from 1.7% to 5.6% between 1973-2013 (p<0.001). Among type II ECs (n=76,118), the proportion of UCS also increased significantly from 6.0% to 17.5% between 1973-2013 (p<0.001). An increasing proportion of UCS was seen in both young and older women but the magnitude of interval increase was larger in the older age group between 1973-2013 (<60 years, from 1.3% to 3.3%. p<0.001; and ≥60 years, from 2.6% to 7.0%, p<0.001).
Conclusion: Our study demonstrated that the proportion of UCS has significantly increased among EC, accounting for more than 5% in recent years.

12

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기